ATLAS fair value
ATLAS has no fair value for this stock today.
Humedix stock price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - Specialty & Generic · KOSDAQ · South Korea
Prices as of Oct 27, 2026 · KRW
ATLAS has no fair value for this stock today.
49%
that it ends higher than today in 21 sessions
ATLAS's own quantitative analysis, all in one place.
Plans from €3.99 a month.
ATLAS's model gives Humedix a 49% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between ₩21,061 and ₩24,826; in 9 out of 10, between ₩18,204 and ₩28,722. Estimated annual volatility is 47%.
ATLAS does not publish a fair value for 200670.KQ right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks 200670.KQ has traded between ₩21,050 and ₩52,700. Today it is 56.5% below that high and 9% above its low.
On the business: net margin is 8.2%; it trades at 29.0 times earnings.
Its beta is 0.37: it tends to move less than the market.
Humedix Co., Ltd. engages in the manufacture and sale of various pharmaceutical products in South Korea. The company offers prescription medicines, active pharmaceutical ingredients, medical devices, cosmetics, and health functional food products.
Want to see everything about Humedix?
Get started →Plans from €3.99 a month.
Other companies in the same line of business:
Humedix Co., Ltd. engages in the manufacture and sale of various pharmaceutical products in South Korea. The company offers prescription medicines, active pharmaceutical ingredients, medical devices, cosmetics, and health functional food products.
49%: close to a coin flip. In half of the simulated outcomes, 200670.KQ ends the month between ₩21,061 and ₩24,826.
Humedix's market capitalization is ₩254B. Its price-to-earnings (P/E) ratio is 29.0: you pay ₩29.0 for each ₩1.00 of yearly earnings.
Yes. 200670.KQ's current dividend yield is 4.82% at today's price (₩22,950).
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer
ATLAS Signals
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy